Sigachi Industries Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9sa29zd2re1j1gt1ccg34v65.pdf

Key Takeaways


The Hyderabad Incident: Fallout & Recovery

Amit Raj Sinha: "Because it is under legal issues, we didn't want to really delay it because in case we get we pump in money and it gets stuck on some legal issue, unnecessarily time and resources will be wasted."

Capacity Expansion: Dahej, Jhagadia & CCS


FY27 Guidance & Margin Trajectory

Amit Raj Sinha: "Sigachi enters FY27 with stable operations, expansion projects progressing in line with the plans, and an organization that has been meaningfully strengthened over the course of the past one year."

API Business: The Second Growth Engine


Customer & Competitive Position

Amit Raj Sinha: "The customers are definitely sticky. There is no second thoughts on that. However, because this is a very small percentage of the total purchase for a formulation mix... the formulation guys always have Vendor 1, Vendor 2, Vendor 3. And the second and the third vendors are usually kept dormant. And when there's a situation across the supplier, they kind of reactivate the Vendor 2 and the Vendor 3."

Balance Sheet & Shareholding


Guidance & Commitments

CommitmentSpecificsTimeline
FY27 revenueINR 650-675 croresFY27 full year
FY27 EBITDA margin18-20%FY27 full year
Dahej 12,000 MTPA MCC CODCOD with ramp-up from ~30% in Q1 to gradual increase through H2End of FY27
CCS facility commercializationRevenue expected immediately upon commercializationQ1 FY28
API revenueMore than INR 100 croresFY27
API PLI benefitINR 8-10 croresFY27
Capacity utilizationNorth of 90%, comfortable near 95-97%FY27
Margin normalcyComplete normalcy in marginsFY27 to mid-FY28
Insurance ad hoc paymentAd hoc amount expectedAround June 25-30, 2025
Promoter shareholdingGradual increase back to 48-49%No date; intention stated
Debt reductionFurther reductionBy end of FY27
INR 1,000 crore turnoverNot in FY28Possibly FY29 or later

Key Metrics

MetricQ4 FY26
Total operating income₹121.89 cr
EBITDA₹15.4 cr, margin 12.63%
Net profit₹7.6 cr, PAT margin 6.23%
FY27 revenue guidance₹650-675 cr
FY27 EBITDA margin guidance18-20%
MCC segment revenue₹85.33 cr
O&M segment revenue₹14.63 cr
API segment revenue₹17.06 cr
Cellulose-based excipient sale quantities14,857 metric tons
MCC capacity utilization82%
Export turnover65% of total revenue, down from 72% last year
API FY26 revenue~₹60 cr
API FY27 expected revenue>₹100 cr
API facility utilization (Grandmax)65-70%
O&M EBITDA margin21-22%
MCC 12,000 MT expansion CapEx₹106 cr
CCS facility total project cost₹90 cr
Total debt outstanding₹145 cr, all working-capital debt
Insurance claim expected₹53.5 cr fixed-asset and inventory loss, plus ₹16.5 cr business-interruption loss